default author photo

Michael Kneba

Schleswig-Holstein University - University Hospital Center

Kiel

Germany

SCHOLARLY PAPERS

2

DOWNLOADS

108

TOTAL CITATIONS

2

Scholarly Papers (2)

1.

Reduction of Chemotherapy in Aggressive Non-Hodgkin's Lymphoma with Favorable Prognosis

Number of pages: 140 Posted: 24 Jun 2019
Westpfalz Hospital, Westpfalz Hospital - Department of Internal Medicine 1, University of Leipzig, Heidelberg University, University of Oslo - Oslo University Hospital, Saarland University - Department of Internal Medicine 1, University of Cologne - University Hospital of Cologne, University Hospital Ulm, University of Tübingen - University Hospitals Tübingen, Rechts der Isar Hospital, Munich University Hospital, University of Göttingen, Hospital Motherhouse of the Borromäerinnen, University of Freiburg - Medical Center, Klinikum-Fulda gAG, University of Oldenburg, University of Hamburg - University Medical Center Hamburg-Eppendorf, Dr. Horst-Schmidt-Klinik, Küchwald Hospital Chemnitz, University Hospital Marburg, Schleswig-Holstein University - University Hospital Center, Hematology AUSL-IRCCS Reggio Emilia, Hematology ASST Spedali Civili Brescia, University of Copenhagen - Rigshospitalet, Università degli studi di Modena e Reggio Emilia (UNIMORE), University Hospital Mannheim, Sapienza University of Rome, Evang. Diakonie-Krankenhaus, University of Wuerzburg - Institute of Pathology, Saarland University - Medical School, University Hospital of North Norway, Tel Aviv University - Rabin Medical Center, Saarland University - Department of Internal Medicine 1, Saarland University - Department of Internal Medicine 1, Saarland University - Department of Internal Medicine 1, Saarland University - Department of Internal Medicine 1, Saarland University - Department of Internal Medicine 1, Asklepios Klinik St. Georg, University of Leipzig, University of Leipzig, Saarland University - Department of Internal Medicine 1 and Independent
Downloads 64 (924,743)

Abstract:

Loading...

2.

Bendamustine, Followed by Ofatumumab and Ibrutinib in Chronic Lymphocytic Leukaemia (CLL2-BIO): Primary Endpoint Analysis of a Multicentre, Open-Label Phase-II Trial

Number of pages: 151 Posted: 23 Feb 2019
University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Würzburg, Tagesklinik Landshut, University of Duisburg-Essen - University Hospital Essen, University Hospital Ulm, Mannheimer Onkologie Praxis, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, Schleswig-Holstein University - University Hospital Center, Schleswig-Holstein University - University Hospital Center, Schleswig-Holstein University - University Hospital Center, University of Cologne - Department I of Internal Medicine, University Hospital Ulm, University of Cologne - Department I of Internal Medicine and University of Cologne - Department I of Internal Medicine
Downloads 44 (1,133,231)
Citation 2

Abstract:

Loading...

chronic lymphocytic leukaemia, ibrutinib, ofatumumab, benadmustine